Dose-escalation study using up to twice the standard dose of cetuximab in patients with metastatic colorectal cancer (mCRC) with no or slight skin reactions on cetuximab standard dose treatment (EVEREST study): Preliminary data.

Tejpar, Sabine; Humblet, Yves; Peeters, Marie-Rose; Gelderblom, H.; Vermorken, J.; Viret, F.; Glimelius, B.; Ciardiello, F.; Kisker, O.; Van Cutsem, Emmanuel

Dose-escalation study using up to twice the standard dose of cetuximab in patients with metastatic colorectal cancer (mCRC) with no or slight skin reactions on cetuximab standard dose treatment (EVEREST study): Preliminary data.

Tejpar, Sabine

;

Humblet, Yves

;

Peeters, Marie-Rose

;

Gelderblom, H.

;

Van Cutsem, Emmanuel

;et.al.

(2006) 42nd Annual Meeting of the American-Society-of-Clinical-Oncology — Location: Atlanta (Ga) (2.June.2006)

Files

No attached file found for this publication.

Details

Authors

Tejpar, SabineUCLouvain
Author
Humblet, YvesUCLouvain
Author
Peeters, Marie-RoseUCLouvain
Author
Gelderblom, H.
Author
Van Cutsem, EmmanuelUCLouvain
Author

Affiliations

Citations

APA
Chicago
FWB

Tejpar, S., Humblet, Y., Peeters, M.-R., Gelderblom, H., Vermorken, J., Viret, F., Glimelius, B., Ciardiello, F., Kisker, O., & Van Cutsem, E. (2006). Dose-escalation study using up to twice the standard dose of cetuximab in patients with metastatic colorectal cancer (mCRC) with no or slight skin reactions on cetuximab standard dose treatment (EVEREST study): Preliminary data. Journal of Clinical Oncology, 24(18), 159S-159S. https://hdl.handle.net/2078.5/139855 (Original work published 2006)